Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study
- PMID: 23254417
- DOI: 10.1093/cid/cis933
Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study
Abstract
Background: We assessed mortality attributable to smoking among patients with human immunodeficiency virus (HIV).
Methods: We estimated mortality rates (MRs), mortality rate ratios (MRRs), life expectancies, life-years lost, and population-attributable risk of death associated with smoking and with HIV among current and nonsmoking individuals from a population-based, nationwide HIV cohort and a cohort of matched HIV-negative individuals.
Results: A total of 2921 HIV patients and 10 642 controls were followed for 14 281 and 45 122 person-years, respectively. All-cause and non-AIDS-related mortality was substantially increased among smoking compared to nonsmoking HIV patients (MRR, 4.4 [95% confidence interval {CI}, 3.0-6.7] and 5.3 [95% CI, 3.2-8.8], respectively). Excess MR per 1000 person-years among current vs nonsmokers was 17.6 (95% CI, 13.3-21.9) for HIV patients and 4.8 (95% CI, 3.2-6.4) for controls. A 35-year-old HIV patient had a median life expectancy of 62.6 years (95% CI, 59.9-64.6) for smokers and 78.4 years (95% CI, 70.8-84.0) for nonsmokers; the numbers of life-years lost in association with smoking and HIV were 12.3 (95% CI, 8.1-16.4) and 5.1 (95% CI, 1.6-8.5). The population-attributable risk of death associated with smoking was 61.5% among HIV patients and 34.2% among controls.
Conclusions: In a setting where HIV care is well organized and antiretroviral therapy is free of charge, HIV-infected smokers lose more life-years to smoking than to HIV. The excess mortality of smokers is tripled and the population-attributable risk of death associated with smoking is doubled among HIV patients compared to the background population.
Similar articles
-
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.AIDS. 2015 Jan 14;29(2):221-9. doi: 10.1097/QAD.0000000000000540. AIDS. 2015. PMID: 25426809 Free PMC article.
-
Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study.Addiction. 2010 Mar;105(3):529-35. doi: 10.1111/j.1360-0443.2009.02827.x. Addiction. 2010. PMID: 20402997
-
Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.Clin Infect Dis. 2008 Nov 15;47(10):1345-53. doi: 10.1086/592692. Clin Infect Dis. 2008. PMID: 18834317
-
Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons.Curr Opin HIV AIDS. 2016 Sep;11(5):514-520. doi: 10.1097/COH.0000000000000306. Curr Opin HIV AIDS. 2016. PMID: 27327615 Review.
-
Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis.AIDS. 2014 Feb 20;28(4):549-58. doi: 10.1097/01.SPC.0000432532.87841.78. AIDS. 2014. PMID: 23921613 Review.
Cited by
-
Mental health and its consequences in people living with HIV: A network approach.Brain Behav. 2024 Oct;14(10):e70021. doi: 10.1002/brb3.70021. Brain Behav. 2024. PMID: 39428553 Free PMC article.
-
The Relationship between Smoking and Susceptibility to HIV Infection: A Two-Sample Mendelian Randomization Analysis.Biomedicines. 2024 Sep 10;12(9):2060. doi: 10.3390/biomedicines12092060. Biomedicines. 2024. PMID: 39335573 Free PMC article.
-
An Analysis of Tobacco and Marijuana Use by Middle School and High School Bisexual and Homosexual Students Surveyed by the National Youth Tobacco Survey From 2020 to 2022.J Prim Care Community Health. 2024 Jan-Dec;15:21501319241276790. doi: 10.1177/21501319241276790. J Prim Care Community Health. 2024. PMID: 39228167 Free PMC article.
-
Interventions for tobacco use cessation in people living with HIV.Cochrane Database Syst Rev. 2024 Aug 5;8(8):CD011120. doi: 10.1002/14651858.CD011120.pub3. Cochrane Database Syst Rev. 2024. PMID: 39101506 Review.
-
Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy.Pathogens. 2024 Jun 27;13(7):540. doi: 10.3390/pathogens13070540. Pathogens. 2024. PMID: 39057767 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
